Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans
Bid Saw UK Pharma Major’s Shares Rise
Executive Summary
GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.
You may also be interested in...
Ipsen To Exit Consumer Health And Focus On Specialty Pharma
The French group is sharpening its focus on specialty care in oncology, rare disease and neuroscience, so is looking to divest its consumer health division to Mayoly Spindler.
Xevudy Helps GSK Ride Out Depressed Shingrix Sales
GlaxoSmithKline is preparing for the long-awaited spin-out of its consumer division later this year but needs to see Shingrix bounce back from its pandemic blues to help the company reignite growth.
With Investor Support Thin On The Ground, Unilever Won't Up Bid For GSK Consumer Healthcare
Unilever's decision not to increase its £50bn bid for GSK Consumer Healthcare has been widely welcomed by analysts. But they warn that the aborted move for GSK has damaged investor confidence in Unilever’s management.